Go Pro
→ This tiny piece of glass could be bigger than GPUs (From Brownstone Research) (Ad)tc pixel Free APLT Stock Alerts

Applied Therapeutics (APLT) Financials

Applied Therapeutics logo
$0.10 0.00 (0.00%)
As of 07/24/2026
Compare
Annual Income Statements for Applied Therapeutics

Annual Income Statements for Applied Therapeutics

This table shows Applied Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -46 -94 -106 -83 -120 -106
Consolidated Net Income / (Loss)		 -46 -94 -106 -83 -120 -106
Net Income / (Loss) Continuing Operations		 -45 -93 -105 -83 -120 -106
Total Pre-Tax Income 		-46 -94 -105 -83 -120 -106
Total Operating Income		 -46 -94 -106 -83 -65 -104
Total Gross Profit		 0.00 0.00 0.00 0.00 9.99 0.00
Total Revenue		 0.00 0.00 0.00 0.00 9.99 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 46 94 106 83 75 105
Selling, General & Admin Expense		 13 33 43 27 21 56
Research & Development Expense		 32 62 63 56 54 49
Total Other Income / (Expense), net		 0.07 0.51 0.56 0.44 -55 -1.33
Interest & Investment Income		 0.09 0.56 0.56 0.69 1.37 3.53
Other Income / (Expense), net		 -0.02 -0.05 0.00 -0.24 -57 -4.86
Basic Earnings per Share		 ($3.55) ($4.28) ($4.12) ($2.18) ($1.42) ($0.76)
Weighted Average Basic Shares Outstanding		 12.83M 21.97M 25.60M 37.83M 84.24M 139.53M
Diluted Earnings per Share		 ($3.55) ($4.28) ($4.12) ($2.18) ($1.42) ($0.76)
Weighted Average Diluted Shares Outstanding		 12.83M 21.97M 25.60M 37.83M 84.24M 139.53M

Quarterly Income Statements for Applied Therapeutics

This table shows Applied Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -42 -38 -84 2.90 -69 44 -22 -21 -19
Consolidated Net Income / (Loss)		 -42 -38 -84 2.90 -69 44 -22 -21 -19
Net Income / (Loss) Continuing Operations		 -42 -38 -84 2.90 -69 44 -22 -21 -19
Total Pre-Tax Income 		-42 -38 -84 2.90 -69 44 -22 -21 -19
Total Operating Income		 -15 -21 -21 -20 -30 -33 -26 -23 -17
Total Gross Profit		 0.00 -0.67 0.00 0.00 0.00 - 0.00 0.00 1.00
Total Revenue		 0.00 -0.67 0.00 0.00 0.00 - 0.00 0.00 1.00
Operating Revenue		 - - - - - - - - 1.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 15 20 21 21 30 33 26 23 18
Selling, General & Admin Expense		 4.71 5.04 9.07 11 15 21 18 13 8.16
Research & Development Expense		 11 15 12 10 15 12 7.84 9.92 9.60
Total Other Income / (Expense), net		 -27 -17 -63 23 -39 77 3.70 1.77 -2.23
Interest & Investment Income		 0.39 0.35 0.59 0.63 1.36 0.96 0.62 0.36 0.14
Other Income / (Expense), net		 -27 -17 -63 23 -40 76 3.08 1.40 -2.38
Basic Earnings per Share		 ($0.47) ($0.40) ($0.67) $0.02 ($0.48) $0.37 ($0.15) ($0.15) ($0.13)
Weighted Average Basic Shares Outstanding		 90.67M 84.24M 125.32M 143.93M 144.35M 139.53M 144.79M 145.09M 145.56M
Diluted Earnings per Share		 ($0.47) ($0.40) ($0.67) ($0.13) ($0.48) $0.52 ($0.15) ($0.15) ($0.13)
Weighted Average Diluted Shares Outstanding		 90.67M 84.24M 125.32M 152.39M 144.35M 139.53M 144.79M 145.09M 145.56M
Weighted Average Basic & Diluted Shares Outstanding		 77.23M 105.89M 114.27M 114.85M 116.36M 0.00 141.58M 144.01M 144.30M

Annual Cash Flow Statements for Applied Therapeutics

This table details how cash moves in and out of Applied Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 0.10 39 -3.58 -37 33 30
Net Cash From Operating Activities		 -36 -78 -91 -78 -55 -84
Net Cash From Continuing Operating Activities		 -36 -78 -91 -78 -55 -84
Net Income / (Loss) Continuing Operations		 -46 -94 -106 -83 -120 -106
Consolidated Net Income / (Loss)		 -46 -94 -106 -83 -120 -106
Amortization Expense		 0.02 2.93 4.70 4.03 2.47 0.99
Non-Cash Adjustments To Reconcile Net Income		 5.97 4.44 6.34 5.96 62 18
Changes in Operating Assets and Liabilities, net		 3.21 8.38 3.82 -5.74 0.11 2.52
Net Cash From Investing Activities		 -20 -19 12 13 14 0.00
Net Cash From Continuing Investing Activities		 -20 -19 12 13 14 0.00
Sale and/or Maturity of Investments		 0.00 115 134 77 14 0.00
Net Cash From Financing Activities		 56 136 75 28 75 114
Net Cash From Continuing Financing Activities		 56 136 75 28 75 114
Repayment of Debt		 0.00 -2.15 -4.72 -3.27 -1.86 -0.31
Issuance of Common Equity		 19 134 74 28 65 105
Other Financing Activities, net		 35 5.04 5.01 3.15 12 9.37

Quarterly Cash Flow Statements for Applied Therapeutics

This table details how cash moves in and out of Applied Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Change in Cash & Equivalents		 1.84 12 97 -24 -23 -19 -29 -20 -18
Net Cash From Operating Activities		 -15 -17 -19 -23 -23 -19 -29 -20 -18
Net Cash From Continuing Operating Activities		 -15 -17 -19 -23 -23 -19 -29 -20 -18
Net Income / (Loss) Continuing Operations		 -42 -38 -84 2.90 -69 44 -22 -21 -19
Consolidated Net Income / (Loss)		 -42 -38 -84 2.90 -69 44 -22 -21 -19
Amortization Expense		 0.51 0.39 0.50 0.30 0.10 0.08 0.10 0.11 0.11
Non-Cash Adjustments To Reconcile Net Income		 29 19 66 -21 42 -69 -1.71 0.57 3.41
Changes in Operating Assets and Liabilities, net		 -1.85 1.70 -1.14 -4.81 2.99 5.49 -5.20 0.31 -2.93
Net Cash From Financing Activities		 17 29 115 -1.69 - - 0.00 - -0.08
Net Cash From Continuing Financing Activities		 17 29 115 -1.69 - - 0.00 - -0.08
Issuance of Common Equity		 6.72 30 107 -2.00 - - 0.00 - 0.02
Other Financing Activities, net		 10 0.00 9.06 0.31 - - 0.00 - -0.09

Annual Balance Sheets for Applied Therapeutics

This table presents Applied Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 20 48 105 90 38 55 87
Total Current Assets		 20 46 103 88 37 54 84
Cash & Equivalents		 19 19 57 54 17 50 79
Prepaid Expenses		 1.50 7.30 5.76 7.57 6.67 4.23 4.25
Other Current Assets		 - - - - 0.06 0.25 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 2.23 1.91 1.30 1.06 0.45 3.05
Other Noncurrent Operating Assets		 0.00 2.23 1.91 1.30 1.06 0.45 3.05
Total Liabilities & Shareholders' Equity		 20 48 105 90 38 55 87
Total Liabilities		 4.43 16 23 27 34 72 30
Total Current Liabilities		 4.43 14 21 26 33 71 27
Accounts Payable		 3.02 8.79 0.64 9.46 4.53 1.74 4.43
Accrued Expenses		 1.41 4.95 20 17 15 15 16
Other Current Liabilities		 - 0.36 0.41 0.44 14 54 6.72
Total Noncurrent Liabilities		 0.00 1.68 1.33 0.89 0.88 0.80 2.39
Other Noncurrent Operating Liabilities		 - 1.68 1.33 0.89 0.88 0.80 2.39
Total Equity & Noncontrolling Interests		 -20 33 82 63 4.06 -17 57
Total Preferred & Common Equity		 -20 33 82 63 4.06 -17 57
Preferred Stock		 - - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -20 33 82 63 4.06 -17 57
Common Stock		 1.67 99 243 329 353 451 631
Retained Earnings		 -21 -67 -161 -266 -349 -469 -574

Quarterly Balance Sheets for Applied Therapeutics

This table presents Applied Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 45 151 128 107 57 37 34
Total Current Assets		 44 151 128 105 54 35 32
Cash & Equivalents		 37 146 122 99 51 30 12
Prepaid Expenses		 7.03 4.17 5.12 5.48 3.20 4.09 20
Other Current Assets		 - 0.25 0.25 0.25 0.00 0.00 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.71 0.33 0.21 1.96 2.94 2.83 2.72
Other Noncurrent Operating Assets		 0.71 0.33 0.21 1.96 2.94 2.83 2.72
Total Liabilities & Shareholders' Equity		 45 151 128 107 57 37 34
Total Liabilities		 56 84 55 101 20 20 35
Total Current Liabilities		 56 84 55 99 18 18 33
Accounts Payable		 6.01 4.02 2.68 2.84 4.87 4.86 4.80
Accrued Expenses		 12 15 10 13 9.46 11 23
Other Current Liabilities		 37 65 42 83 3.64 2.22 4.61
Total Noncurrent Liabilities		 0.74 0.04 0.03 1.71 2.27 2.16 2.03
Other Noncurrent Operating Liabilities		 0.74 0.04 0.03 1.71 2.27 2.16 2.03
Total Equity & Noncontrolling Interests		 -11 67 72 5.89 37 17 -0.56
Total Preferred & Common Equity		 -11 67 72 5.89 37 17 -0.56
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -11 67 72 5.89 37 17 -0.56
Common Stock		 420 620 622 624 633 635 636
Retained Earnings		 -431 -553 -550 -618 -596 -617 -636

Annual Metrics And Ratios for Applied Therapeutics

This table displays calculated financial ratios and metrics derived from Applied Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
DEI Shares Outstanding		 17,134,190.00 22,488,081.00 26,215,514.00 48,058,956.00 77,229,207.00 116,356,474.00
DEI Adjusted Shares Outstanding		 17,134,190.00 22,488,081.00 26,215,514.00 48,058,956.00 77,229,207.00 116,356,474.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.66 -4.18 -4.03 -1.72 -1.55 -0.91
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth		 0.00% -100.93% -10.19% 21.56% -49.91% 8.85%
EBIT Growth		 0.00% -107.25% -11.74% 21.23% -45.61% 9.89%
NOPAT Growth		 0.00% -107.24% -11.81% 21.46% 22.20% -61.62%
Net Income Growth		 0.00% -106.45% -12.37% 21.86% -45.15% 11.81%
EPS Growth		 0.00% -20.56% 3.74% 47.09% 34.86% 46.48%
Operating Cash Flow Growth		 0.00% -115.41% -16.01% 13.93% 29.35% -52.80%
Free Cash Flow Firm Growth		 0.00% 0.00% -22.36% 28.87% 90.71% -2,430.62%
Invested Capital Growth		 0.00% -138.35% -24.14% -43.47% -152.82% 66.60%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -6.26% 100.00%
EBITDA Q/Q Growth		 0.00% -5,066.81% -3.01% 13.01% -25.13% 42.75%
EBIT Q/Q Growth		 0.00% 0.00% -2.98% 12.76% -23.85% 42.62%
NOPAT Q/Q Growth		 0.00% 0.00% -3.29% 8.94% -3.25% -13.02%
Net Income Q/Q Growth		 0.00% 0.00% -3.40% 13.37% -24.09% 43.61%
EPS Q/Q Growth		 0.00% 0.00% 1.20% 33.54% -47.92% 54.76%
Operating Cash Flow Q/Q Growth		 0.00% -15.24% -4.84% 12.39% -2.06% -3.01%
Free Cash Flow Firm Q/Q Growth		 0.00% -606.10% -11.57% -3.98% 85.91% -484.70%
Invested Capital Q/Q Growth		 -183.05% -9.77% 16.37% 29.75% -38.23% 75.92%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -1,187.53% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -645.80% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -1,212.20% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -1,198.47% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.50% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.80% 99.41% 99.47% 99.18% 98.87% 96.76%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -187.97% -164.06% -146.16% -247.77% 1,830.54% -529.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -259.96% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -257.01% 0.00%
Return on Common Equity (ROCE)		 -50.52% -164.06% -146.16% -247.77% 1,830.54% -529.97%
Return on Equity Simple (ROE_SIMPLE)		 -139.58% -114.67% -168.83% -2,031.72% 698.49% -185.29%
Net Operating Profit after Tax (NOPAT)		 -32 -66 -74 -58 -45 -73
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -452.06% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -35.02% -41.03% -35.59% -43.80% -185.36% -50.45%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 263.47% -128.07%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 206.37% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 539.43% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 745.80% 0.00%
Earnings before Interest and Taxes (EBIT)		 -46 -95 -106 -83 -121 -109
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -46 -92 -101 -79 -119 -108
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 14.34 6.04 3.75 8.99 0.00 1.75
Price to Tangible Book Value (P/TBV)		 14.34 6.04 3.75 8.99 0.00 1.75
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 25.89 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 20.90 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.19 -1.18 -1.23 -1.68 6.15 -3.24
Leverage Ratio		 1.42 1.33 1.35 1.93 -7.12 3.55
Compound Leverage Factor		 1.41 1.33 1.34 1.91 -7.04 3.44
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 13.52 8.96 -2.05 -19.13 -17.28 -10.63
Noncontrolling Interest Sharing Ratio		 73.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 3.27 4.83 3.34 1.12 0.76 3.06
Quick Ratio		 2.76 4.56 3.05 0.91 0.70 2.91
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -57 -70 -50 -4.65 -118
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.21 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -6.25 -15 -18 -27 -67 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.21 0.00
Increase / (Decrease) in Invested Capital		 0.00 -8.64 -3.59 -8.04 -41 45
Enterprise Value (EV)		 429 398 154 5.94 209 20
Market Capitalization		 467 495 235 37 259 100
Book Value per Share		 $1.90 $3.64 $2.39 $0.08 ($0.22) $0.49
Tangible Book Value per Share		 $1.90 $3.64 $2.39 $0.08 ($0.22) $0.49
Total Capital		 33 82 63 4.06 -17 57
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -39 -97 -81 -31 -50 -79
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.80 -15 -19 -27 -67 -23
Debt-free Net Working Capital (DFNWC)		 32 81 62 3.88 -17 56
Net Working Capital (NWC)		 32 81 62 3.88 -17 56
Net Nonoperating Expense (NNE)		 14 28 32 24 75 33
Net Nonoperating Obligations (NNO)		 -39 -97 -81 -31 -50 -79
Total Depreciation and Amortization (D&A)		 0.02 2.93 4.70 4.03 2.47 0.99
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -667.41% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -168.08% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -168.08% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.28) ($4.12) ($2.18) ($1.42) ($0.76)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 26.01M 25.60M 37.83M 84.24M 139.53M
Adjusted Diluted Earnings per Share		 $0.00 ($4.28) ($4.12) ($2.18) ($1.42) ($0.76)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 26.01M 25.60M 37.83M 84.24M 139.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.28) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 21.97M 26.22M 48.11M 105.89M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -32 -66 -74 -58 -45 -73
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -452.06% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -1,198.47% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.74% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Applied Therapeutics

This table displays calculated financial ratios and metrics derived from Applied Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
DEI Shares Outstanding		 63,124,227.00 77,229,207.00 105,886,831.00 114,267,382.00 114,846,271.00 116,356,474.00 116,356,474.00 141,575,526.00 144,012,125.00
DEI Adjusted Shares Outstanding		 63,124,227.00 77,229,207.00 105,886,831.00 114,267,382.00 114,846,271.00 116,356,474.00 116,356,474.00 141,575,526.00 144,012,125.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.67 -0.49 -0.79 0.03 -0.60 0.38 -0.19 -0.15 -0.13
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -129.21% -172.67% -786.47% 108.78% -65.29% 214.58% 73.41% -938.54% 72.76%
EBIT Growth		 -121.24% -158.71% -716.03% 107.57% -63.58% 213.18% 73.44% -1,055.68% 72.65%
NOPAT Growth		 19.95% -10.72% -94.26% -70.00% -91.95% -124.58% -21.01% 20.90% 43.66%
Net Income Growth		 -121.82% -161.13% -728.04% 109.80% -61.89% 216.79% 74.00% -836.02% 72.31%
EPS Growth		 -17.50% -766.67% -272.22% 64.86% -2.13% 230.00% 77.61% -15.38% 72.92%
Operating Cash Flow Growth		 24.05% -7.00% -170.54% -37.34% -58.43% -14.49% -51.43% 9.98% 21.13%
Free Cash Flow Firm Growth		 -104.50% 592.26% 556.72% 24.32% 25,130.58% -400.82% -321.61% -400.62% -489.79%
Invested Capital Growth		 -28.48% -152.82% -193.42% -24.67% -91.70% 66.60% 82.20% 73.93% 86.55%
Revenue Q/Q Growth		 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -44.21% 10.93% -123.24% 103.06% -2,813.44% 161.74% -151.81% 3.39% 11.87%
EBIT Q/Q Growth		 -42.61% 11.07% -122.26% 102.69% -3,181.41% 161.54% -152.15% 3.35% 11.80%
NOPAT Q/Q Growth		 9.79% -35.57% -0.41% -38.43% -1.86% -58.61% 45.89% 9.51% 27.45%
Net Income Q/Q Growth		 -43.25% 11.07% -122.77% 103.45% -2,466.84% 164.16% -149.59% 2.27% 10.97%
EPS Q/Q Growth		 -27.03% 14.89% -67.50% 80.60% -269.23% 208.33% -128.85% 0.00% 13.33%
Operating Cash Flow Q/Q Growth		 10.49% -15.48% -11.21% -19.48% -3.25% 16.55% -47.09% 28.97% 9.54%
Free Cash Flow Firm Q/Q Growth		 99.32% 27,423.60% 44.98% -128.28% 323.47% -428.38% -6.81% 36.13% -73.99%
Invested Capital Q/Q Growth		 -21.40% -38.23% -18.12% 37.11% -86.68% 75.92% 37.06% 7.88% 3.67%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,902.30%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,675.80%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,913.40%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,899.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.08% 99.08% 99.31% 127.67% 98.06% 102.24% 97.23% 98.32% 99.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 13,641.41% 1,830.54% -612.33% -473.39% 7,271.35% -529.97% -83.71% -150.82% -680.47%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -27.15%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -26.95%
Return on Common Equity (ROCE)		 13,641.41% 1,830.54% -612.33% -473.39% 7,271.35% -529.97% -83.71% -150.82% -680.47%
Return on Equity Simple (ROE_SIMPLE)		 873.90% 0.00% -287.64% 0.00% 0.00% 0.00% -118.66% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -15 -15 -20 -21 -33 -18 -16 -12
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,173.06%
Net Nonoperating Expense Percent (NNEP)		 -74.32% -57.10% -81.67% 29.58% -70.08% 119.15% -4.01% -6.76% -13.10%
Return On Investment Capital (ROIC_SIMPLE)		 - 85.76% - -28.24% -353.36% -57.93% -48.73% -92.72% 2,091.02%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 815.70%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 960.10%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,775.80%
Earnings before Interest and Taxes (EBIT)		 -43 -38 -85 2.27 -70 43 -22 -22 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -38 -84 2.57 -70 43 -22 -22 -19
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 10.70 7.37 165.68 1.75 1.55 2.53 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 10.70 7.37 165.68 1.75 1.55 2.53 0.00
Price to Revenue (P/Rev)		 14.74 25.89 0.00 0.00 0.00 0.00 0.00 0.00 87.11
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 11.23 20.90 0.00 0.00 0.00 0.00 0.00 0.00 75.17
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 59.95 6.15 -2.68 -2.32 26.46 -3.24 -1.90 -1.70 -20.79
Leverage Ratio		 -72.00 -7.12 2.87 2.52 -29.46 3.55 2.00 1.84 26.44
Compound Leverage Factor		 -71.34 -7.06 2.85 3.22 -28.89 3.63 1.95 1.81 26.24
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -14.85 -12.28 -1.29 0.49 -4.41 -4.84 -13.52 -23.20 -26.27
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.80 0.76 1.80 2.30 1.06 3.06 3.00 1.94 0.96
Quick Ratio		 0.67 0.70 1.75 2.21 1.00 2.91 2.83 1.71 0.36
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.09 26 37 -11 24 -78 -83 -53 -92
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.21 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -49 -67 -79 -50 -93 -22 -14 -13 -13
Invested Capital Turnover		 -0.25 -0.21 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Increase / (Decrease) in Invested Capital		 -11 -41 -52 -9.86 -44 45 65 37 80
Enterprise Value (EV)		 120 209 574 411 877 20 6.12 14 75
Market Capitalization		 157 259 720 534 976 100 57 44 87
Book Value per Share		 ($0.18) ($0.22) $0.64 $0.63 $0.05 $0.49 $0.32 $0.12 $0.00
Tangible Book Value per Share		 ($0.18) ($0.22) $0.64 $0.63 $0.05 $0.49 $0.32 $0.12 $0.00
Total Capital		 -11 -17 67 72 5.89 57 37 17 -0.56
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -37 -50 -146 -122 -99 -79 -51 -30 -12
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -48 -67 -79 -50 -93 -23 -15 -14 -13
Debt-free Net Working Capital (DFNWC)		 -11 -17 67 72 5.64 56 36 17 -1.25
Net Working Capital (NWC)		 -11 -17 67 72 5.64 56 36 17 -1.25
Net Nonoperating Expense (NNE)		 32 23 69 -23 48 -77 3.96 5.16 7.26
Net Nonoperating Obligations (NNO)		 -37 -50 -146 -122 -99 -79 -51 -30 -12
Total Depreciation and Amortization (D&A)		 0.51 0.39 0.50 0.30 0.10 0.08 0.10 0.11 0.11
Debt-free, Cash-free Net Working Capital to Revenue		 -454.72% -667.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,319.30%
Debt-free Net Working Capital to Revenue		 -103.34% -168.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -124.80%
Net Working Capital to Revenue		 -103.34% -168.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -124.80%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.47) ($0.40) ($0.67) $0.02 ($0.48) $0.37 ($0.15) ($0.15) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding		 90.67M 84.24M 125.32M 143.93M 144.35M 139.53M 144.79M 145.09M 145.56M
Adjusted Diluted Earnings per Share		 ($0.47) ($0.40) ($0.67) ($0.13) ($0.48) $0.52 ($0.15) ($0.15) ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding		 90.67M 84.24M 125.32M 152.39M 144.35M 139.53M 144.79M 145.09M 145.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 77.23M 105.89M 114.27M 114.85M 116.36M 0.00 141.58M 144.01M 144.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -15 -15 -14 -21 -23 -18 -16 -12
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,173.06%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,899.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Applied Therapeutics (NASDAQ: APLT) showed a mixed but still highly challenged financial profile in Q3 2025. The company posted only $1.0 million in revenue, while operating expenses remained far higher than sales. That resulted in a quarterly net loss of $19.0 million and continued negative operating cash flow. On the balance sheet, cash fell sharply from the prior quarter, and shareholder equity remained slightly negative.

  • Revenue improved to $1.0 million in Q3 2025, compared with $0 in Q2 2025 and Q1 2025.
  • The quarterly net loss of $19.0 million was smaller than the $21.3 million loss in Q2 2025 and the $21.8 million loss in Q1 2025.
  • Operating cash burn improved slightly, with cash used in operations narrowing to -$18.4 million from -$20.3 million in Q2 2025.
  • The company still had $11.9 million in cash and equivalents at quarter-end, providing some liquidity.
  • Prepaid expenses and other current assets remained meaningful on the balance sheet, but these are not a substitute for cash generation.
  • R&D spending of $9.6 million remained a major cost, reflecting continued investment in the pipeline.
  • SG&A expense was $8.2 million, down from $13.2 million in Q2 2025, showing some reduction in overhead.
  • Revenue is still far too small to cover the cost structure, with operating expenses of $17.8 million against just $1.0 million in sales.
  • Cash and equivalents dropped from $30.4 million in Q2 2025 to $11.9 million in Q3 2025.
  • The balance sheet showed a negative total common equity of $561,000, indicating ongoing balance-sheet stress.

Looking at the broader trend over the last four quarters, Applied Therapeutics has been burning cash consistently. Operating cash flow was negative in every quarter shown, including -$28.6 million in Q1 2025, -$20.3 million in Q2 2025, and -$18.4 million in Q3 2025. That is an improvement, but it still signals a company that is consuming cash faster than it is generating it.

The income statement also shows that profitability remains a major problem. Applied Therapeutics has not built a recurring revenue base yet, and losses have stayed substantial despite some quarter-to-quarter improvement. In Q3 2025, operating loss was $16.8 million, and pre-tax loss was $19.0 million. For retail investors, that means the company’s future still depends heavily on clinical progress, commercialization success, or additional financing.

Balance sheet trends are also important here. Cash rose and fell sharply throughout the last year, and Q3 2025 ended with materially less liquidity than Q1 2025. At the same time, total liabilities were $34.9 million versus total assets of $34.4 million, leaving equity slightly negative. That is a warning sign for investors watching dilution and financing risk.

Bottom line: Applied Therapeutics showed a small improvement in revenue and losses in Q3 2025, but the company is still operating with minimal sales, ongoing cash burn, and a fragile balance sheet. The stock remains highly dependent on future clinical and funding developments.

07/26/26 04:42 AM ETAI Generated. May Contain Errors.

Applied Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Applied Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Applied Therapeutics' net income appears to be on an upward trend, with a most recent value of -$105.62 million in 2024, rising from -$45.51 million in 2019. The previous period was -$119.76 million in 2023. See where experts think Applied Therapeutics is headed by visiting Applied Therapeutics' forecast page.

Applied Therapeutics' total operating income in 2024 was -$104.30 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $104.75 million

Over the last 5 years, Applied Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

Applied Therapeutics' total liabilities were at $29.69 million at the end of 2024, a 58.8% decrease from 2023, and a 570.4% increase since 2018.

In the past 6 years, Applied Therapeutics' cash and equivalents has ranged from $16.66 million in 2022 to $79.40 million in 2024, and is currently $79.40 million as of their latest financial filing in 2024.

Over the last 5 years, Applied Therapeutics' book value per share changed from 1.90 in 2019 to 0.49 in 2024, a change of -74.3%.


Related Companies

Financial statements for NASDAQ:APLT last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The 90%-off options that empty accounts
A call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...
Profits Run | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The Weekly Options Trick Wall Street Doesn't Advertise
The most profitable trading desks don't guess market direction, they collect income regardless of it. A 25-yea...
Base Camp Trading | Sponsoredtc pixel
Have you seen Elon’s new “supercurrency”? (It affects you)
Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...
StocksToTrade | Sponsoredtc pixel